INNOVENT ANNOUNCES PHASE 3 CREDIT-5 STUDY MET PRIMARY ENDPOINT, SINTBILO® (TAFOLECIMAB INJECTION) AS FIRST-LINE MONOTHERAPY TREATMENT FOR HYPERLIPIDEMIA DEMONSTRATED POTENT LIPID-LOWERING EFFICACY

Reuters · 2d ago

Please log in to view news